NYSE:AGN - Allergan Stock Price, Price Target & More

$165.58 -1.25 (-0.75 %)
(As of 04/19/2018 06:06 AM ET)
Previous Close$166.83
Today's Range$165.45 - $167.65
52-Week Range$142.81 - $256.80
Volume1.46 million shs
Average Volume3.13 million shs
Market Capitalization$58.11 billion
P/E Ratio10.13
Dividend Yield1.73%

About Allergan (NYSE:AGN)

Allergan logoAllergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.38%
Current Ratio1.16%
Quick Ratio1.06%


Trailing P/E Ratio10.13
Forward P/E Ratio10.62
P/E Growth1.19

Sales & Book Value

Annual Sales$15.94 billion
Price / Sales3.62
Cash Flow$39.8029 per share
Price / Cash4.16
Book Value$207.19 per share
Price / Book0.80


EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-26.32%
Return on Equity8.43%
Return on Assets4.75%


Outstanding Shares348,340,000

How to Become a New Pot Stock Millionaire

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Friday, February 9th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share on Wednesday, March 28th. This represents a $2.88 dividend on an annualized basis and a yield of 1.74%. The ex-dividend date is Tuesday, February 27th. This is an increase from Allergan's previous quarterly dividend of $0.70. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its board has authorized a share repurchase program on Tuesday, September 26th 2017, which authorizes the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its shares are undervalued.

How were Allergan's earnings last quarter?

Allergan (NYSE:AGN) announced its quarterly earnings results on Tuesday, February, 6th. The company reported $4.86 earnings per share for the quarter, beating the consensus estimate of $4.74 by $0.12. The business earned $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The company's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period last year, the company posted $3.90 EPS. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of $15.25-16.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.42. The company issued revenue guidance of $15.0-15.3 billion, compared to the consensus revenue estimate of $15.25 billion.Allergan also updated its Q1 guidance to $3.20-3.40 EPS.

What price target have analysts set for AGN?

21 brokerages have issued twelve-month price objectives for Allergan's stock. Their predictions range from $160.07 to $265.00. On average, they expect Allergan's share price to reach $220.9035 in the next twelve months. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:
  • 1. Cantor Fitzgerald analysts commented, "Key takeaways from the quarter: 1) AGN has more important pipeline catalysts in 2018 including those for the CGRPs for migraine, abicipar for AMD, and the FDA approval of Esmya. 2) LOEs and mix will impact AGN’s margins in the near term, but its cost-cutting initiatives will buffer the impact with longer- term margin expansion driven by pipeline success. 3) ~One-third of AGN’s sales comes from cash pay products and Botox Therapeutics, and AGN believes this will grow to ~45% of sales by 2022. 4) Capital allocation strategy is sound with AGN on its way to achieving a 3x leverage ratio, and maintaining its investment grade rating, AGN will be opportunistic on its $2B share buyback and is committed to growing its dividend. 5) As of 12/31/17, AGN had cash & equivalents of $6.5B and debt of $30.1B, CFLO from operations increased to ~$2.1B in 4Q17. 6) Top line results from ACHIEVE I (UBR-MD-01) study demonstrated efficacy, safety and tolerability, study met co-primary endpoints in the first of two Phase 3 studies, there were 6 cases with aminotransferase (ALT or AST) elevations greater than 3x the upper limit of normal, and there were alternative explanations in all cases." (2/6/2018)
  • 2. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)

Are investors shorting Allergan?

Allergan saw a decrease in short interest in the month of March. As of March 15th, there was short interest totalling 6,391,424 shares, a decrease of 39.1% from the February 28th total of 10,501,103 shares. Based on an average daily trading volume, of 4,617,063 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.9% of the shares of the company are short sold.

Who are some of Allergan's key competitors?

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Chief Exec. Officer and Pres (Age 48)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
  • Mr. James C. D'Arecca, Chief Accounting Officer (Age 47)

Has Allergan been receiving favorable news coverage?

Headlines about AGN stock have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan earned a coverage optimism score of 0.02 on Accern's scale. They also assigned news stories about the company an impact score of 45.84 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $165.58.

How big of a company is Allergan?

Allergan has a market capitalization of $58.11 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]

MarketBeat Community Rating for Allergan (AGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  1,002 (Vote Outperform)
Underperform Votes:  456 (Vote Underperform)
Total Votes:  1,458
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergan (NYSE:AGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Allergan in the last 12 months. Their average twelve-month price target is $220.9035, suggesting that the stock has a possible upside of 33.41%. The high price target for AGN is $265.00 and the low price target for AGN is $160.07. There are currently 7 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.702.612.60
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $220.9035$223.7405$227.1294$251.9444
Price Target Upside: 33.41% upside33.93% upside30.54% upside33.11% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Stifel NicolausInitiated CoverageHold -> Hold$192.00LowView Rating Details
4/16/2018CowenSet Price TargetBuy$255.00LowView Rating Details
4/12/2018Cantor FitzgeraldSet Price TargetHold$191.00LowView Rating Details
4/12/2018Deutsche BankReiterated RatingBuyLowView Rating Details
3/26/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/15/2018JPMorgan ChaseSet Price TargetBuy$265.00LowView Rating Details
3/14/2018Royal Bank of CanadaReiterated RatingBuy$213.00LowView Rating Details
3/1/2018Credit Suisse GroupSet Price TargetBuy$215.00LowView Rating Details
3/1/2018Morgan StanleyLower Price TargetOverweight -> Overweight$200.00 -> $181.00HighView Rating Details
2/23/2018SunTrust BanksInitiated CoverageBuy -> Buy$200.00LowView Rating Details
2/7/2018Bank of AmericaBoost Price TargetBuy -> Buy$208.00 -> $215.00LowView Rating Details
1/29/2018BarclaysUpgradeEqual Weight -> Overweight$220.00 -> $230.00LowView Rating Details
1/10/2018UBSSet Price TargetBuy$250.00MediumView Rating Details
1/9/2018CitigroupLower Price TargetBuy$215.00N/AView Rating Details
1/5/2018Wells FargoSet Price TargetBuy$245.00LowView Rating Details
12/7/2017ArgusDowngradeBuy -> Hold$256.80 -> $160.07LowView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/13/2017Piper JaffraySet Price TargetHold$227.00N/AView Rating Details
5/10/2017Goldman SachsDowngradeBuy -> Neutral$262.00HighView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 4/19/2016 forward)


Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$3.37$3.39$3.38
Q2 20183$3.17$3.92$3.67
Q3 20183$3.85$3.89$3.87
Q4 20183$4.39$4.81$4.56

Allergan (NYSE AGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$3.39N/AView Earnings Details
2/6/2018Q4 2017$4.74$4.86$4.2813 billion$4.3261 billionViewListenView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.0377 billion$4.0340 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.9461 billion$4.0074 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.5325 billion$3.5730 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.9018 billion$1.9105 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.6460 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.5977 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.9857 billion$1.9898 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/14/2012Q4 2011$1.75$1.77ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
7/26/2011Q2 2011$1.00$1.01ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/15/2011Q4 2010$0.93$0.93ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
11/4/2010Q3 2010$0.84$0.85ViewN/AView Earnings Details
8/5/2010Q2 2010$0.81$0.83ViewN/AView Earnings Details
5/10/2010Q1 2010$0.74$0.63ViewN/AView Earnings Details
2/23/2010Q4 2009$0.72$0.85ViewN/AView Earnings Details
11/4/2009Q3 2009$0.65$0.66ViewN/AView Earnings Details
7/29/2009Q2 2009$0.57$0.61ViewN/AView Earnings Details
4/30/2009Q1 2009$0.49$0.58ViewN/AView Earnings Details
2/19/2009Q4 2008$0.50$0.53ViewN/AView Earnings Details
10/29/2008Q3 2008$0.46$0.48ViewN/AView Earnings Details
8/6/2008Q2 2008$0.48$0.48ViewN/AView Earnings Details
5/1/2008Q1 2008$0.51$0.55ViewN/AView Earnings Details
2/20/2008Q4 2007$0.31$0.35ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Allergan (NYSE:AGN) Dividend Information

Allergan pays an annual dividend of $2.88 per share, with a dividend yield of 1.74%. AGN's most recent quarterly dividend payment was Wednesday, March 28. Allergan pays out 17.61% of its earnings out as a dividend.
Most Recent Dividend:3/28/2018
Annual Dividend:$2.88
Dividend Yield:1.74%
Dividend Growth:141.00% (3 Year Average)
Payout Ratio:17.61% (Trailing 12 Months of Earnings)
18.47% (Based on This Year's Estimates)
17.42% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 77.95%
Insider Trading History for Allergan (NYSE:AGN)
Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Maria Teresa HiladoInsiderBuy895$167.39$149,814.05View SEC Filing  
3/8/2018Brent L. SaundersCEOBuy3,300$152.53$503,349.00View SEC Filing  
3/8/2018Matthew M. WalshCFOBuy1,000$153.96$153,960.00View SEC Filing  
3/5/2018Joseph H. BoccuziDirectorBuy900$143.42$129,078.00View SEC Filing  
2/21/2018Matthew M WalshCFOBuy2,000$160.94$321,880.00View SEC Filing  
2/14/2018William MeuryInsiderSell58,879$160.62$9,457,144.98View SEC Filing  
12/7/2017Chris W. BodineDirectorBuy3,030$164.77$499,253.10View SEC Filing  
12/6/2017Brent L. SaundersChairmanBuy4,600$164.74$757,804.00View SEC Filing  
12/5/2017Christopher J. CoughlinDirectorBuy10,000$163.30$1,633,000.00View SEC Filing  
12/1/2017William MeuryInsiderSell11,807$173.89$2,053,119.23View SEC Filing  
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00274,226View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.0812,659View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.7711,957View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.905,242View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.004,062View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00421,755View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00132,862View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.008,223View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.0012,723View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.0011,600View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.0016,591View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.006,401View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.748,220View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.0017,327View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.0017,327View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.007,142View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.0082,776View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.008,142View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.0097,373View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.0092,776View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00469,232View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.6433,812View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.009,142View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.0080,470View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00132,776View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.0119,608View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.0097,373View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.0027,942View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.0016,871View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.0019,970View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.0012,941View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.2873,891View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Allergan (NYSE AGN) News Headlines

Allergan (AGN) Given Average Rating of "Hold" by BrokeragesAllergan (AGN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 3:40 AM
Allergan to Post Q1 2018 Earnings of $3.39 Per Share, SunTrust Banks Forecasts (AGN)Allergan to Post Q1 2018 Earnings of $3.39 Per Share, SunTrust Banks Forecasts (AGN)
www.americanbankingnews.com - April 18 at 7:58 AM
Stifel Says Allergan Could Use A Face-Lift, Initiates Coverage With HoldStifel Says Allergan Could Use A Face-Lift, Initiates Coverage With Hold
finance.yahoo.com - April 17 at 3:43 PM
New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM ...New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM ...
globenewswire.com - April 17 at 10:45 AM
Allergan to pay $3.5 mln over US claims of defective Lap-BandsAllergan to pay $3.5 mln over US claims of defective Lap-Bands
www.reuters.com - April 17 at 10:45 AM
Allergan (AGN) Downgraded by VetrAllergan (AGN) Downgraded by Vetr
www.americanbankingnews.com - April 17 at 9:25 AM
Stifel Nicolaus Initiates Coverage on Allergan (AGN)Stifel Nicolaus Initiates Coverage on Allergan (AGN)
www.americanbankingnews.com - April 17 at 7:39 AM
Allergan (AGN) Given a $255.00 Price Target at CowenAllergan (AGN) Given a $255.00 Price Target at Cowen
www.americanbankingnews.com - April 16 at 12:05 PM
Form DEFA14A Allergan plcForm DEFA14A Allergan plc
www.streetinsider.com - April 16 at 10:27 AM
Allergan (AGN) Price Target Raised to $278.00 at Wells FargoAllergan (AGN) Price Target Raised to $278.00 at Wells Fargo
www.americanbankingnews.com - April 13 at 6:01 PM
What does Allergan plc’s (NYSE:AGN) Balance Sheet Tell Us About Its Future?What does Allergan plc’s (NYSE:AGN) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - April 13 at 3:39 PM
Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual ...Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual ...
www.prnewswire.com - April 13 at 11:00 AM
Pfizer, Allergan Win Out With Tax BenefitsPfizer, Allergan Win Out With Tax Benefits
www.bloomberg.com - April 12 at 3:40 PM
Allergan (AGN) Given a $191.00 Price Target at Cantor FitzgeraldAllergan (AGN) Given a $191.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 12 at 3:26 PM
Allergan (AGN) Earns Outperform Rating from Wells FargoAllergan (AGN) Earns Outperform Rating from Wells Fargo
www.americanbankingnews.com - April 12 at 2:19 PM
Deutsche Bank Reiterates Buy Rating for Allergan (AGN)Deutsche Bank Reiterates Buy Rating for Allergan (AGN)
www.americanbankingnews.com - April 12 at 11:07 AM
Allergan (AGN) Downgraded by BidaskClub to "Hold"Allergan (AGN) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 11 at 10:42 PM
Plaintiffs Class Counsel Announce Settlement of the Allergan, Inc. Proxy Violation Securities LitigationPlaintiffs' Class Counsel Announce Settlement of the Allergan, Inc. Proxy Violation Securities Litigation
www.prnewswire.com - April 11 at 11:17 AM
Global Hyperhidrosis Therapeutics Pipeline Analysis Report 2017 with Key Players Dermira, Allergan and TheraVida ...Global Hyperhidrosis Therapeutics Pipeline Analysis Report 2017 with Key Players Dermira, Allergan and TheraVida ...
www.prnewswire.com - April 10 at 3:33 PM
Allergan Stock Performance in 1Q18Allergan Stock Performance in 1Q18
finance.yahoo.com - April 10 at 3:33 PM
Analyst Recommendations for Teva Pharmaceutical in April 2018Analyst Recommendations for Teva Pharmaceutical in April 2018
finance.yahoo.com - April 10 at 10:57 AM
Allergan (AGN) Earns Hold Rating from Cantor FitzgeraldAllergan (AGN) Earns Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 10 at 9:17 AM
Allergan (AGN) Expected to Announce Quarterly Sales of $3.59 BillionAllergan (AGN) Expected to Announce Quarterly Sales of $3.59 Billion
www.americanbankingnews.com - April 10 at 2:54 AM
Biotech Analysis Central Pharma News: Allergan And Richters Success, Sellas Life Sciences Breast Cancer Data ...Biotech Analysis Central Pharma News: Allergan And Richter's Success, Sellas Life Sciences' Breast Cancer Data ...
seekingalpha.com - April 9 at 10:54 AM
$3.35 EPS Expected for Allergan (AGN) This Quarter$3.35 EPS Expected for Allergan (AGN) This Quarter
www.americanbankingnews.com - April 8 at 3:10 PM
Allergan (AGN) Rating Reiterated by BarclaysAllergan (AGN) Rating Reiterated by Barclays
www.americanbankingnews.com - April 8 at 2:39 PM
Allergan (AGN) Given a $255.00 Price Target by UBS AnalystsAllergan (AGN) Given a $255.00 Price Target by UBS Analysts
www.americanbankingnews.com - April 6 at 10:54 PM
Deutsche Bank Analysts Give Allergan (AGN) a $251.00 Price TargetDeutsche Bank Analysts Give Allergan (AGN) a $251.00 Price Target
www.americanbankingnews.com - April 6 at 10:54 PM
Allergan (AGN) Downgraded by Zacks Investment ResearchAllergan (AGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:16 PM
Allergan (AGN) Stock Rating Reaffirmed by Wells FargoAllergan (AGN) Stock Rating Reaffirmed by Wells Fargo
www.americanbankingnews.com - April 6 at 4:46 PM
JPMorgan Chase Analysts Give Allergan (AGN) a $275.00 Price TargetJPMorgan Chase Analysts Give Allergan (AGN) a $275.00 Price Target
www.americanbankingnews.com - April 6 at 12:43 PM
Global Biosimilars Markets to 2022 Featuring Profiles of Key Players - Allergan, Bioton, Cinnagen, Emcure Pharma, LG ...Global Biosimilars Markets to 2022 Featuring Profiles of Key Players - Allergan, Bioton, Cinnagen, Emcure Pharma, LG ...
www.businesswire.com - April 6 at 11:21 AM
FY2019 EPS Estimates for Allergan plc Cut by SunTrust Banks (AGN)FY2019 EPS Estimates for Allergan plc Cut by SunTrust Banks (AGN)
www.americanbankingnews.com - April 6 at 8:23 AM
Allergans Vraylar Meets Endpoints in Bipolar I Phase IIIAllergan's Vraylar Meets Endpoints in Bipolar I Phase III
www.nasdaq.com - April 5 at 6:15 AM
Allergan (AGN) PT Set at $250.00 by Royal Bank of CanadaAllergan (AGN) PT Set at $250.00 by Royal Bank of Canada
www.americanbankingnews.com - April 4 at 4:44 PM
Allergan's Vraylar Meets Endpoints in Bipolar I Phase IIIAllergan's Vraylar Meets Endpoints in Bipolar I Phase III
finance.yahoo.com - April 4 at 2:27 PM
Why It Makes Sense For Allergan To Sell Its Women's Health UnitWhy It Makes Sense For Allergan To Sell Its Women's Health Unit
finance.yahoo.com - April 3 at 3:35 PM
Allergan (AGN) Possible Sale of Womens Health Business an Important Step Forward - RBCAllergan (AGN) Possible Sale of Women's Health Business an 'Important Step Forward' - RBC
www.streetinsider.com - April 3 at 10:57 AM
Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I ...Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I ...
www.prnewswire.com - April 3 at 10:57 AM
Allergan mulling sale of womens health unitAllergan mulling sale of women's health unit
seekingalpha.com - April 2 at 4:46 PM
Cantor Fitzgerald Analysts Give Allergan (AGN) a $231.00 Price TargetCantor Fitzgerald Analysts Give Allergan (AGN) a $231.00 Price Target
www.americanbankingnews.com - April 2 at 12:58 PM
Royal Bank of Canada Lowers Allergan (AGN) Price Target to $221.00Royal Bank of Canada Lowers Allergan (AGN) Price Target to $221.00
www.americanbankingnews.com - April 2 at 8:39 AM
Allergan (AGN) Rating Reiterated by Wells FargoAllergan (AGN) Rating Reiterated by Wells Fargo
www.americanbankingnews.com - April 2 at 12:30 AM
Allergan (AGN) Price Target Cut to $200.00Allergan (AGN) Price Target Cut to $200.00
www.americanbankingnews.com - April 1 at 10:52 PM
Allergan plc (AGN) Short Interest UpdateAllergan plc (AGN) Short Interest Update
www.americanbankingnews.com - April 1 at 2:50 AM
Allergan (AGN) Lowered to "Hold" at ValuEngineAllergan (AGN) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - March 31 at 3:48 PM
Allergan (AGN) Stock Rating Lowered by Zacks Investment ResearchAllergan (AGN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:16 PM
Drug companies want Supreme Court to take eye drop disputeDrug companies want Supreme Court to take eye drop dispute
marketbeat.com - March 31 at 8:13 AM
Allergan (AGN) PT Lowered to $215.00Allergan (AGN) PT Lowered to $215.00
www.americanbankingnews.com - March 30 at 12:13 PM
Allergan (AGN) Rating Reiterated by Deutsche BankAllergan (AGN) Rating Reiterated by Deutsche Bank
www.americanbankingnews.com - March 29 at 10:16 PM

SEC Filings

Allergan (NYSE:AGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement


Allergan (NYSE AGN) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.